home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480517.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
2KB
|
40 lines
Document 0517
DOCN M9480517
TI Transient bacteremia due to Mycobacterium avium complex in patients with
AIDS.
DT 9410
AU Kemper CA; Havlir D; Bartok AE; Kane C; Camp B; Lane N; Deresinski SC;
Department of Medicine, Santa Clara Valley Medical Center, San; Jose, CA
95128.
SO J Infect Dis. 1994 Aug;170(2):488-93. Unique Identifier : AIDSLINE
MED/94308628
AB It is generally assumed that Mycobacterium avium complex (MAC)
bacteremia, once it develops, is unremitting. On the basis of this
presumption, changes in the level of mycobacteremia are used to gauge
therapeutic response. In 7 (12%) of 60 patients enrolled in a
prospective trial of MAC bacteremia and AIDS, bacteremia became
undetectable before the initiation of antimycobacterial therapy.
Patients with transient bacteremia reported fewer and shorter symptoms
and survived longer than those with sustained bacteremia (59 vs. 31
weeks; P = .022). There was no difference in the duration of AIDS, CD4+
cell count, hematocrit, or body weight between groups. Two additional
patients with transient bacteremia were identified outside this study
setting. Despite disappearance of detectable mycobacteremia and
subsequent administration of antimycobacterial agent(s), bacteremia once
again became detectable in 6 patients 4-45 weeks after their negative
pretreatment cultures. Patients with disseminated MAC may have
fluctuating levels of mycobacteremia that become undetectable in the
absence of antimycobacterial therapy.
DE Adult AIDS-Related Opportunistic Infections/DRUG THERAPY/*ETIOLOGY/
MORTALITY Bacteremia/DRUG THERAPY/*ETIOLOGY/MORTALITY
Clofazimine/THERAPEUTIC USE Drug Therapy, Combination
Ethambutol/THERAPEUTIC USE Human Life Tables Mycobacterium
avium-intracellulare Infection/DRUG THERAPY/ *ETIOLOGY/MORTALITY
Prospective Studies Recurrence Rifampin/THERAPEUTIC USE Risk Factors
Support, Non-U.S. Gov't Survival Analysis CLINICAL TRIAL JOURNAL
ARTICLE RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).